Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk EvaluationBettina Lickiss 1, Matthias Gossmann 1, Peter Linder 1, Ulrich Thomas 2, Elena Dragicevic 2, Marta Lemme 2, Michael George 2, Niels Fertig 2, Sonja Stölzle-Feix 2
1innoVitro GmbH, 2Nanion Technologies GmbH
The analysis of changes in contractile function and cellular integrity of human iPSC-derived cardiomyocytes is of immense importance for nonclinical drug development. A hybrid 96-well cell analysis system addresses both parameters in a real-time and physiological manner for reliable, human-relevant results, necessary for a safe transition into clinical stages.
